IDEAYA Biosciences, Inc. (IDYA) Financial Statements
IDEAYA Biosciences, Inc. (IDYA) reported trailing twelve-month revenue of $234.1M (up 3024.4% year on year) and net income of -$175.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$113.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IDYAIDEAYA Biosciences, Inc.Follow IDYA — free
—
Price chart with a free account
- Market cap
- 3.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.02 | 0.03 | 0.05 | 0.02 | 0.01 | 0.22 | 0.23 | |
| Research & development | 0.04 | 0.06 | 0.09 | 0.13 | 0.29 | 0.31 | 0.37 | |
| Operating income | -0.04 | -0.05 | -0.06 | -0.13 | -0.33 | -0.16 | -0.22 | |
| Pre-tax income | -0.03 | -0.05 | -0.06 | -0.11 | -0.27 | -0.11 | -0.18 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.03 | -0.05 | -0.06 | -0.11 | -0.27 | -0.11 | -0.18 | |
| Diluted EPS ($) | -1.40 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 | -1.94 | |
| Diluted shares (bn) | — | — | 0.041 | 0.058 | 0.082 | 0.088 | — |
USD billions · SEC XBRL
IDEAYA Biosciences, Inc. — questions
- What is IDEAYA Biosciences, Inc.'s revenue?
- $234.1M over the twelve months to 2026-06-30, up 3024.4% year on year, from its 10-Q and 10-K filings.
- What is IDEAYA Biosciences, Inc.'s net income?
- -$175.0M over the twelve months to 2026-06-30.
- What is IDEAYA Biosciences, Inc.'s free cash flow?
- -$113.9M over the twelve months to 2026-06-30.
- What are IDEAYA Biosciences, Inc.'s diluted earnings per share?
- $-1.94 over the twelve months to 2026-06-30.
Every figure on this page comes from IDEAYA Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.